Search:
Computing and Library Services - delivering an inspiring information environment

In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog

Wong, Charng Choon, Periasamy, Nararajan, Sagineedu, Sreenivasa R., Sidik, Shiran, Sumon, Shariful Hasan, Loadman, Paul M., Phillips, Roger M., Lajis, Nordin Haji and Stanslas, Johnson (2014) In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog. Investigational new drugs, 32 (5). pp. 806-814. ISSN 0167-6997

Metadata only available from this repository.

Abstract

Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor anti- tumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer mul- ticell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anti- cancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90 ± 0.20 μM/min/cm2 and 0.56 ± 0.06 μM/min/ cm2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.

Item Type: Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Schools: School of Applied Sciences
Related URLs:
Depositing User: Roger Phillips
Date Deposited: 12 May 2015 14:01
Last Modified: 14 May 2015 10:52
URI: http://eprints.hud.ac.uk/id/eprint/24436

Downloads

Downloads per month over past year

Repository Staff Only: item control page

View Item View Item

University of Huddersfield, Queensgate, Huddersfield, HD1 3DH Copyright and Disclaimer All rights reserved ©